$1.72 Billion is the total value of Sofinnova Investments, Inc.'s 61 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 44.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| KRTX | Karuna Therapeutics Inc | $466,308,000 | +77.8% | 2,073,124 | 0.0% | 27.13% | +24.2% | |
| Buy | CinCor Pharma Inc | $199,544,000 | +90.0% | 6,079,949 | +9.1% | 11.61% | +32.8% | |
| NTRA | Natera Inc | $135,972,000 | +23.6% | 3,102,960 | 0.0% | 7.91% | -13.6% | |
| VERA | Vera Therapeutics Inccl a | $67,797,000 | +56.6% | 3,181,442 | 0.0% | 3.94% | +9.4% | |
| AVTE | Aerovate Therapeutics Inc | $62,319,000 | +6.1% | 3,758,686 | 0.0% | 3.63% | -25.9% | |
| ASND | Ascendis Pharma A/Ssponsored adr | $51,612,000 | +11.1% | 499,824 | 0.0% | 3.00% | -22.4% | |
| MRK | Buy | Merck & Co Inc | $50,248,000 | +52.7% | 583,468 | +61.6% | 2.92% | +6.7% |
| SNY | Buy | Sanofi SAsponsored adr | $48,078,000 | +240.5% | 1,264,546 | +348.1% | 2.80% | +137.8% |
| QQQ | New | Invesco QQQ Trust Series 1put | $40,089,000 | – | 150,000 | +100.0% | 2.33% | – |
| AZN | Buy | AstraZeneca PLCsponsored adr | $38,491,000 | +84.1% | 701,878 | +121.9% | 2.24% | +28.7% |
| XLV | Health Care Select Sector SPDRput | $36,333,000 | -5.6% | 300,000 | 0.0% | 2.11% | -34.0% | |
| IWM | New | iShares Russell 2000 ETFput | $32,984,000 | – | 200,000 | +100.0% | 1.92% | – |
| YMAB | Y-mAbs Therapeutics Inc | $31,641,000 | -4.7% | 2,194,278 | 0.0% | 1.84% | -33.4% | |
| UTHR | Buy | United Therapeutics Corp | $30,897,000 | +23.3% | 147,564 | +38.7% | 1.80% | -13.9% |
| GILD | New | Gilead Sciences Inc | $29,759,000 | – | 482,400 | +100.0% | 1.73% | – |
| MRK | New | Merck & Co Inccall | $25,836,000 | – | 300,000 | +100.0% | 1.50% | – |
| BMRN | Sell | Biomarin Pharmaceutical Inc | $24,986,000 | -0.0% | 294,750 | -2.3% | 1.45% | -30.1% |
| CTIC | Buy | CTI Biopharma Corp | $21,024,000 | +30.2% | 3,612,376 | +33.6% | 1.22% | -9.1% |
| RETA | Buy | Reata Pharmaceuticals Inccl a | $20,566,000 | -13.7% | 818,376 | +4.4% | 1.20% | -39.7% |
| ISRG | New | Intuitive Surgical Inc | $18,050,000 | – | 96,300 | +100.0% | 1.05% | – |
| IRTC | Sell | iRhythm Technologies Inc | $17,551,000 | +14.3% | 140,095 | -1.4% | 1.02% | -20.1% |
| DXCM | Buy | Dexcom Inc | $16,587,000 | +17.7% | 205,948 | +8.9% | 0.96% | -17.8% |
| SRPT | Buy | Sarepta Therapeutics Inc | $15,635,000 | +58.9% | 141,440 | +7.8% | 0.91% | +11.1% |
| CYTK | Sell | Cytokinetics Inc | $15,539,000 | +23.3% | 320,722 | -0.0% | 0.90% | -13.9% |
| ISEE | Buy | Iveric Bio Inc | $14,723,000 | +134.4% | 820,665 | +25.7% | 0.86% | +63.9% |
| LLY | New | Lilly Eli & Co | $14,712,000 | – | 45,500 | +100.0% | 0.86% | – |
| ZNTL | Buy | Zentalis Pharmaceuticals Inc | $12,636,000 | +36.9% | 583,357 | +77.6% | 0.74% | -4.3% |
| SNDX | Buy | Syndax Pharmaceuticals Inc | $12,616,000 | +58.6% | 525,002 | +27.0% | 0.73% | +10.9% |
| EW | New | Edwards Lifesciences Corp | $12,163,000 | – | 147,200 | +100.0% | 0.71% | – |
| AKUS | Akouos Inc | $10,242,000 | +44.1% | 1,515,074 | 0.0% | 0.60% | +0.7% | |
| RCUS | New | Arcus Biosciences Inc | $9,976,000 | – | 381,345 | +100.0% | 0.58% | – |
| INZY | Inozyme Pharm Inc | $9,796,000 | -43.8% | 3,655,308 | 0.0% | 0.57% | -60.7% | |
| IDYA | New | IDEAYA Biosciences Inc | $9,769,000 | – | 654,756 | +100.0% | 0.57% | – |
| TVTX | Buy | Travere Therapeutics Inc | $9,725,000 | +88.8% | 394,678 | +85.6% | 0.57% | +31.9% |
| RXDX | Sell | Prometheus Biosciences Inc | $8,248,000 | -24.4% | 139,774 | -63.8% | 0.48% | -47.1% |
| INBX | Buy | Inhibrx Inc | $8,081,000 | +381.3% | 450,177 | +204.3% | 0.47% | +235.7% |
| NXTC | Nextcure Inc | $7,348,000 | -41.5% | 2,671,856 | 0.0% | 0.43% | -59.1% | |
| ACET | Sell | Adicet Bio Inc | $6,996,000 | -7.6% | 491,965 | -5.1% | 0.41% | -35.4% |
| FULC | New | Fulcrum Therapeutics Inc | $6,450,000 | – | 797,262 | +100.0% | 0.38% | – |
| INBX | New | Inhibrx Incput | $6,283,000 | – | 350,000 | +100.0% | 0.37% | – |
| NCNA | Nucana Biomedsponsored adr | $5,852,000 | +44.1% | 5,599,999 | 0.0% | 0.34% | +0.6% | |
| RGNX | Sell | Regenxbio Inc | $5,655,000 | -70.5% | 213,959 | -72.5% | 0.33% | -79.4% |
| KDNY | Buy | Chinook Therapeutics Inc | $5,660,000 | +17.0% | 287,901 | +4.1% | 0.33% | -18.4% |
| GRTX | Galera Therapeutics Inc | $5,366,000 | +33.8% | 3,083,712 | 0.0% | 0.31% | -6.6% | |
| IMTX | Sell | Immatics NV | $5,325,000 | -52.8% | 532,516 | -58.9% | 0.31% | -67.0% |
| ARQT | New | Arcutis Biotherapeutics Inc | $5,242,000 | – | 274,330 | +100.0% | 0.30% | – |
| AGEN | Buy | Agenus Inc | $4,997,000 | +170.4% | 2,437,465 | +155.8% | 0.29% | +89.0% |
| INSM | Buy | Insmed Inc | $4,753,000 | +3177.9% | 220,665 | +2894.1% | 0.28% | +2208.3% |
| BOLT | Bolt Biotherapeutics Inc | $4,077,000 | -27.4% | 2,754,437 | 0.0% | 0.24% | -49.4% | |
| GERN | Sell | Geron Corp | $2,783,000 | -35.7% | 1,189,208 | -57.4% | 0.16% | -55.0% |
| Nucana Biomedordinary shares | $2,508,000 | +44.1% | 2,400,000 | 0.0% | 0.15% | +0.7% | ||
| GERN | Buy | Geron Corpcall | $2,509,000 | +61.9% | 1,072,100 | +7.2% | 0.15% | +13.2% |
| IMGN | Sell | ImmunoGen Inc | $2,401,000 | -53.2% | 502,393 | -56.0% | 0.14% | -67.3% |
| NGM | New | NGM Biopharmaceuticals Inccall | $1,962,000 | – | 150,000 | +100.0% | 0.11% | – |
| OBSV | ObsEva SA | $675,000 | -91.2% | 4,749,623 | 0.0% | 0.04% | -93.9% | |
| SYBX | Synlogic Inc | $546,000 | -17.4% | 574,972 | 0.0% | 0.03% | -41.8% | |
| PDSB | PDS Biotechnology Corporation | $424,000 | -18.6% | 142,635 | 0.0% | 0.02% | -41.9% | |
| FUSN | Buy | Fusion Pharmaceuticals Inc | $352,000 | +81.4% | 117,099 | +50.0% | 0.02% | +25.0% |
| PTGX | Exit | Protagonist Therapeutics Inccall | $0 | – | -100,000 | -100.0% | -0.07% | – |
| CLDX | Exit | Celldex Therapeutics Inc | $0 | – | -48,304 | -100.0% | -0.11% | – |
| JNCE | Exit | Jounce Therapeutics Inc | $0 | – | -981,928 | -100.0% | -0.25% | – |
| Exit | Amylyx Pharmaceuticals Inc | $0 | – | -187,381 | -100.0% | -0.30% | – | |
| XNCR | Exit | Xencor Inc | $0 | – | -158,164 | -100.0% | -0.36% | – |
| SGEN | Exit | Seagen Inc | $0 | – | -27,894 | -100.0% | -0.41% | – |
| ARGX | Exit | argenx SEsponsored adr | $0 | – | -15,000 | -100.0% | -0.47% | – |
| CCXI | Exit | ChemoCentryx Inccall | $0 | – | -250,000 | -100.0% | -0.52% | – |
| HZNP | Exit | Horizon Therapeutics PLC | $0 | – | -100,297 | -100.0% | -0.67% | – |
| CCXI | Exit | ChemoCentryx Inc | $0 | – | -636,659 | -100.0% | -1.31% | – |
| VRTX | Exit | Vertex Pharmaceuticals Inc | $0 | – | -74,758 | -100.0% | -1.75% | – |
| XBI | Exit | SPDR S&P Biotech ETFput | $0 | – | -400,000 | -100.0% | -2.47% | – |
| NVO | Exit | Novo-Nordisk A Sadr | $0 | – | -273,873 | -100.0% | -2.54% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-08
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Natera, Inc. | 23 | Q3 2023 | 20.5% |
| Ascendis Pharma A/S | 23 | Q3 2023 | 27.9% |
| NuCana plc | 23 | Q3 2023 | 15.2% |
| Synlogic Inc. (fmrly Mirna) | 22 | Q2 2023 | 0.9% |
| Y-mAbs Therapeutics, Inc. | 21 | Q3 2023 | 6.5% |
| ObsEva SA | 20 | Q4 2022 | 11.0% |
| Nucana PLC | 19 | Q3 2023 | 9.7% |
| SYNDAX PHARMACEUTICALS INC | 19 | Q3 2023 | 2.2% |
| PDS Biotechnology Corporation | 19 | Q3 2023 | 0.1% |
| Karuna Therapeutics, Inc. | 18 | Q3 2023 | 27.1% |
View Sofinnova Investments, Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| OTONOMY, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Sofinnova Investments, Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
View Sofinnova Investments, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.